01:05 PM EST - WPD Pharmaceuticals Inc. : Announced that its license partner Moleculin Biotech, Inc. (Nasdaq: MBRX)(“Moleculin”), has entered into an agreement with a leading government funded research facility in the United States to conduct research on its patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus. WPD Pharmaceuticals Inc.
shares WBIO:CNX are trading off 2 cents at $0.75.
